Recently, the authoritative list of the top 100 enterprises in Xiangjiang New Area for 2025 was released. Tat Ka Wai Hong, with its comprehensive strength and social contribution, has successfully been selected as one of the top 100 private enterprises in Xiangjiang New Area in four categories: “revenue scale”, “tax contribution”, “research and development investment”, and “social responsibility”. Against the backdrop of continuous optimization of the business environment in Hunan and the focus on promoting high-quality industrial development in Xiangjiang New Area, Tat Ka Wai Hong has taken advantage of the situation and demonstrated its strong business expansion capabilities and stable operational strength with the fourth highest revenue scale and thirteenth highest tax contribution; Furthermore, with the responsibility of donating scholarships, supporting rural revitalization, caring for vulnerable groups, serving innovation and entrepreneurship, building a traditional Chinese medicine science and culture museum, and promoting traditional Chinese medicine culture, we have been awarded the first place in the “social responsibility” ranking.

This list is selected by the Hunan Xiangjiang New Area (Yuelu District) Federation of Industry and Commerce in accordance with the requirements of the Hunan Xiangjiang New Area Party Working Committee and Management Committee, based on the main evaluation indicators of the operating (output) income, tax amount, research and development investment amount, and employment absorption of private enterprises within the scope of Hunan Xiangjiang New Area in 2024.

Tat Ka Wai Hong adheres to the development strategy of “innovation oriented, ecological chain oriented, and talent based”, achieving a revenue of 5.233 billion yuan in 2024, a year-on-year increase of 34.07%, and paying over 150 million yuan in taxes. It has formed a good development trend of leading pharmaceutical research and development, deepening hospital distribution, expanding professional pharmacies, and coordinating the pharmaceutical industry, and actively layout innovative drug research and development, application of regenerative medicine technology, and expansion of Hong Kong, Macao, and overseas markets.

Tat Ka Wai Hong will continue to lead the direction with strategy, drive growth with innovation, closely focus on the goal of “industrial strength zone” in Xiangjiang New Area, and focus on the strategic positioning of “minor disease experts, chronic disease managers, and major disease consultants”. We will build an integrated service system of prevention, diagnosis, treatment, insurance (risk), and care, so that patients can “run fewer errands, spend less money, and take good care of their illnesses”. With professionalism and dedication, we will warm people’s hearts with services, and make greater contributions to the takeoff of Xiangjiang New Area, industry progress, and social development!